Quidel Corp QDEL expects Q1 FY22 gross sales of $990 million – $1 billion, up 164% – 166% Y/Y, beating the consensus of $817.30 million.
- The corporate expects COVID-19 product revenues of $836 million, together with roughly $657 million in QuickVue COVID-19 check income and roughly $138 million in Sofia SARS antigen check income.
- “Within the first quarter of 2022, we bought roughly 113 million QuickVue COVID-19 antigen exams and about 12 million Sofia SARS antigen exams,” stated Douglas Bryant, President, and CEO.
- Additionally Learn: Quidel’s This autumn Earnings Beat Avenue View Regardless of 21% Decline In Gross sales.
- “We additionally expanded our put in base of Sofia analyzers to 79,000 instrument placements, which additional widens our point-of-care footprint and will increase alternatives to introduce our full portfolio of assays to sufferers and healthcare suppliers,” Bryant added.
- Value Motion: QDEL shares closed 0.39% increased at $118.10 throughout after-hours buying and selling on Thursday.
